Other Non-Current Liabilities
Vertex Pharmaceuticals Other Non-Current Liabilities decreased by 1.1% to $1.26B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 31.9%, from $951.90M to $1.26B. Over 5 years (FY 2020 to FY 2025), Other Non-Current Liabilities shows an upward trend with a 63.6% CAGR. This is a positive signal — lower values indicate better performance for this metric.
Analysis
How to read this metric
An increase may indicate rising long-term operational risks or deferred tax burdens, while a decrease suggests the settlement of these obligations.
Detailed definition
This represents miscellaneous long-term obligations that do not fit into standard categories like long-term debt or pens...
Peer comparison
Peers in the medical device and pharmaceutical sectors often hold similar balances related to deferred tax liabilities and long-term environmental or legal accruals.
other_non_current_liabilitiesHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $107.69M | $108.47M | $303.30M | $117.40M | $115.40M | $115.70M | $685.80M | $726.50M | $759.30M | $869.30M | $877.70M | $853.60M | $876.80M | $933.30M | $1.01B | $951.90M | $1.20B | $1.23B | $1.27B | $1.26B |
| QoQ Change | — | +0.7% | +179.6% | -61.3% | -1.7% | +0.3% | +492.7% | +5.9% | +4.5% | +14.5% | +1.0% | -2.7% | +2.7% | +6.4% | +8.7% | -6.2% | +25.6% | +3.2% | +2.9% | -1.1% |
| YoY Change | — | — | — | — | +7.2% | +6.7% | +126.1% | +518.8% | +558.0% | +651.3% | +28.0% | +17.5% | +15.5% | +7.4% | +15.6% | +11.5% | +36.3% | +32.2% | +25.1% | +31.9% |
Other Non-Current Liabilities at Other Companies
Frequently Asked Questions
- What is Vertex Pharmaceuticals's other non-current liabilities?
- Vertex Pharmaceuticals (VRTX) reported other non-current liabilities of $1.26B in Q1 2026.
- How has Vertex Pharmaceuticals's other non-current liabilities changed year-over-year?
- Vertex Pharmaceuticals's other non-current liabilities increased by 31.9% year-over-year, from $951.90M to $1.26B.
- What is the long-term trend for Vertex Pharmaceuticals's other non-current liabilities?
- Over 5 years (2020 to 2025), Vertex Pharmaceuticals's other non-current liabilities has grown at a 63.6% compound annual growth rate (CAGR), from $108.40M to $1.27B.
- What does other non-current liabilities mean?
- Miscellaneous long-term financial obligations not classified under standard debt or liability categories.